FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Clinical trials for FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA trials appear
Sign up with your email to follow new studies for FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to outsmart Platinum-Resistant ovarian cancer
Disease control OngoingThis study tests whether combining two drugs, cediranib and olaparib, works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum-based chemo. About 582 women will be randomly assign…
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 08:00 UTC
-
New drug combo may outperform chemo for returning ovarian cancer
Disease control OngoingThis study tests whether olaparib (a targeted drug) alone or combined with cediranib (which blocks tumor blood vessels) works better than standard platinum chemo for women whose ovarian, fallopian tube, or peritoneal cancer has returned after initial treatment. About 579 particip…
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to outsmart Chemo-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug called peposertib combined with a standard chemotherapy (PLD) in people with ovarian or related cancers that have stopped responding to platinum-based treatment. The main goal is to find the safest dose and understand side effects. About 54…
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for recurrent ovarian cancer: drug combo and surgery may extend life
Disease control OngoingThis study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Measles virus hijacks stem cells to attack ovarian cancer
Disease control OngoingThis early-phase trial tests a new approach for recurrent ovarian, fallopian tube, or peritoneal cancer. Doctors take stem cells from the patient's fat tissue, infect them with a modified measles virus, and inject them into the abdomen. The idea is that the stem cells will delive…
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC